The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

Novo Nordisk (NVO) is making headlines with its inventive investment of $1.2 billion aimed at building a new production ...

Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Not just drugs for obesity and diabetes. The Danish pharmaceutical giant differentiates itself in other sectors ...

The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, making it challenging for Viking. Read why I ...

Danish drugmaker Novo Nordisk (NVO) is investing $1.20 billion U.S. in a new facility that will produce medications to treat ...

The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...

It’s likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo ...

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...